Announcements Trials
Browse Landscape

Phase

Phase 2 139Phase 1 97Phase 1/2 58Phase 3 26Phase 4 11Phase NA 3Phase EARLY_PHASE1 2Phase 2/3 1

Status

Recruiting 3Withdrawn 1Unknown 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Neoplasms 1

Interventions

Cisplatin 22Fluorouracil 21Radiotherapy 18Gemcitabine 17Docetaxel 16Oxaliplatin 15Paclitaxel 14Carboplatin 13Capecitabine 13Bevacizumab 13Leucovorin 11Cyclophosphamide 11Irinotecan 10Drug Therapy 10Cytarabine 9Saline Solution 7Magnetic Resonance Spectroscopy 7Letrozole 7Dexamethasone 7Rituximab 6Nivolumab 6Methotrexate 6Exercise 6Etoposide 6Electroporation 6Doxorubicin 6pembrolizumab 5Pemetrexed 5Metformin 5Melphalan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Completed × Everolimus × Clear all
NCT03285802 2020-02-05

Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation

Greater Baltimore Medical Center

Phase 2/3 Completed
1 enrolled
Gynecologic

Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡